Savara Inc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Savara Inc (SVRA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $35.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-13
- Savara Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $35.40M, a 5.67% increase from fiscal 2024.
- Savara Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $33.50M, a 45.65% increase from fiscal 2023.
- Savara Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $23.00M, a 641.94% increase from fiscal 2022.
- Savara Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $3.10M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $35.40M 10-K · filed 2026-03-13 |
| 2024-12-31 | $33.50M 10-K · filed 2026-03-13 |
| 2023-12-31 | $23.00M 10-K · filed 2025-03-27 |
| 2022-12-31 | $3.10M 10-K · filed 2024-03-07 |
| 2021-12-31 | -$10.90M 10-K · filed 2023-03-30 |
| 2020-12-31 | $14.30M 10-K · filed 2022-03-30 |
| 2019-12-31 | $12.80M 10-K · filed 2021-03-10 |
| 2018-12-31 | $8.70M 10-K · filed 2020-03-12 |
| 2017-12-31 | $7.90M 10-K · filed 2019-03-13 |
| 2016-12-31 | $4.00M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |